首页> 外文期刊>Biochemical Pharmacology >Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.
【24h】

Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.

机译:阿瓦西米(CI-1011),一种新型的酰基辅酶A:胆固醇酰基转移酶(ACAT)抑制剂,介导HepG2细胞中含载脂蛋白B脂蛋白合成和分泌抑制的细胞内机制。

获取原文
获取原文并翻译 | 示例
           

摘要

We have studied the cellular and molecular mechanisms involved in the suppression of apoB secretion from HepG2 cells following incubation with avasimibe (CI-1011), a novel inhibitor of acyl-coenzyme A: cholesterol acyltransferase (ACAT). Cellular lipid analysis revealed that avasimibe significantly decreased the synthesis of cholesterol and cholesteryl ester, and, at higher doses, of triglyceride. Time-course trypsin protection assays revealed that avasimibe induced the accumulation of translocationally arrested apoB intracellularly. Pulse-chase studies showed that the treatment with avasimibe induced a >75% decrease in apoB secretion relative to control, but initially enhanced the protein stability and cellular accumulation of apoB. Subcellular fractionation of microsomes further confirmed the accumulation of secretion-incompetent apoB-lipoproteins in the endoplasmic reticulum (ER) and Golgi compartments of avasimibe-treated HepG2 cells. Although incubation of drug-treated cells with carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a potent proteasome inhibitor, increased cellular apoB (70%), it failed to increase apoB secretion. Drug treatment induced an accumulation of secretion-incompetent apoB-containing lipoprotein particles, the majority of which demonstrated a density in a range similar to that of high-density lipoprotein. However, studies in permeabilized cells demonstrated that, at longer chase times, intracellularly accumulated apoB was eventually degraded, indicating that the inhibition of degradation may be transient. Oleate treatment of avasimibe-treated cells partially restored apoB secretion but not to the levels seen in control cells. In summary, we hypothesize that avasimibe acutely blocks the secretion of apoB and its associated lipoproteins from HepG2 cells, transiently enhancing its membrane association and cellular accumulation with eventual intracellular degradation of accumulated apoB.
机译:我们已经研究了与阿瓦西米(CI-1011)(一种新型的酰基辅酶A抑制剂:胆固醇酰基转移酶(ACAT))孵育后,抑制HepG2细胞从apoB分泌中涉及的细胞和分子机制。细胞脂质分析显示,阿瓦西米显着降低胆固醇和胆固醇酯的合成,以及更高剂量的甘油三酸酯的合成。时程胰蛋白酶保护试验表明,阿瓦西米诱导细胞内被转运的停滞的apoB的积累。脉冲追踪研究表明,与对照相比,用阿瓦西米贝治疗引起apoB分泌减少> 75%,但最初增强了apoB的蛋白质稳定性和细胞积累。微粒体的亚细胞分离进一步证实了分泌不适合的载脂蛋白B-脂蛋白在阿伐西米处理的HepG2细胞的内质网(ER)和高尔基体中的积累。尽管将药物处理的细胞与有效的蛋白酶体抑制剂羧苯甲酰基-亮氨酸-亮氨酸-亮氨酸(MG132)一起孵育可增加细胞载脂蛋白B(70%),但未能增加载脂蛋白B的分泌。药物治疗引起了分泌不足的含apoB的脂蛋白颗粒的积累,其中大多数蛋白的密度与高密度脂蛋白相似。然而,在通透性细胞中的研究表明,在更长的追踪时间中,细胞内积累的apoB最终被降解,表明降解的抑制作用可能是短暂的。油酸处理阿瓦西米贝处理的细胞可部分恢复apoB分泌,但不能恢复至对照细胞中的水平。总而言之,我们假设阿瓦西米贝能急性阻止HepG2细胞分泌apoB及其相关的脂蛋白,短暂地增强其膜缔合和细胞积累,并最终导致积累的apoB在细胞内降解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号